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Sexual dysfunction and fertility-related
distress in young adults with cancer over 5
years following diagnosis: study protocol of
the Fex-Can Cohort study
L. Wettergren1* , L. Ljungman1, C. Micaux Obol1, L. E. Eriksson2,3,4 and C. Lampic1,5
Abstract
Background: There is a lack of firm knowledge regarding sexual problems and fertility-related distress in young
adults following a diagnosis with cancer. Establishing such understanding is essential to identify patients in need of
specific support and to develop cancer care accordingly. This study protocol describes the Fex-Can Cohort study, a
population-based prospective cohort study investigating sexual dysfunction and fertility-related distress in young
adults diagnosed with cancer in Sweden. The primary objective of the study is to determine the prevalence and
predictors of sexual dysfunction and fertility-related distress following a cancer diagnosis in young adulthood
compared to prevalence rates for the general population. Further aims are to investigate the trajectories of these
issues over time, the co-existence between sexual dysfunction and fertility-related distress, and the relation
between these issues and body image, anxiety and depression, health-related quality of life, self-efficacy related to
sexuality and fertility, and fertility-related knowledge.
Methods: Participants in the Fex-Can Cohort will be identified via the Swedish National Quality Registries for Brain
Tumors, Breast Cancer, Gynecological Oncology, Lymphoma, and Testicular Cancer. All patients diagnosed at the
ages of 18–39, during a period of 18 months, will be invited to participate. Established instruments will be used to
measure sexual function (PROMIS SexFS), fertility-related distress (RCAC), body image (BIS), anxiety and depression
(HADS), and health-related quality of life (QLQ-C30); Self-efficacy and fertility-related knowledge will be assessed by
study-specific measures. The survey will be administered to participants at baseline (approximately 1.5 year after
diagnosis) and at 3 and 5 years post-diagnosis. Registry data will be used to collect clinical variables. A comparison
group of 2000 young adults will be drawn from the Swedish population register (SPAR) and subsequently
approached with the same measures as the cancer group.
Discussion: The study will determine the prevalence and predictors of sexual dysfunction and fertility-related
distress in young men and women with cancer. The findings will form a basis for developing interventions to
alleviate sexual problems and fertility-related distress in young adults with cancer in the short and long term.
Trial registration: This is an observational cohort study and clinical trial registration was therefore not obtained.
Keywords: Cancer, Cohort study, Fertility-related distress, Sexual function, Young adults
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Background
Cancer affects large groups of young adults, commonly
defined as those between 18 to 39 years of age. Globally
about one million young adults are diagnosed with
cancer yearly, and the corresponding figure in Sweden is
approximately 2000 [1, 2]. In addition to being a life-
threatening condition, cancer and its treatments may
impair several aspects of the general health, including
sexual and reproductive functions. Being diagnosed with
cancer during young adulthood can thus be particularly
distressing by interfering with important life goals, such
as establishing intimate relationships and building a
family [3].
Previous research has reported that over 40% of young
adults with cancer experience sexual problems within
the first 2 years following diagnosis [4, 5]. Problems
commonly reported by women include reduced sexual
desire, vaginal dryness and/or dyspareunia, difficulties in
sexual arousal and/or orgasm, and low satisfaction with
sex life [6–8]. In men diagnosed with cancer erectile
dysfunction, orgasmic difficulties, reduced sexual inter-
est, and low satisfaction with sex life have been reported
[9–12]. Sexual problems can be caused by several of the
cancers common in the age group and their treatments
(i.e., radiation therapy, chemotherapy, endocrine treat-
ment, and surgery), directly or indirectly via physiological,
psychological, and interpersonal factors [13, 14]. However,
firm knowledge about the mechanisms involved in sexual
problems after cancer in young adulthood is not yet estab-
lished. Previous research has indicated that female gender,
higher age, a poor prognosis, and being in a partner rela-
tionship predict more sexual problems [4].
Several cancer types and their treatments may cause tem-
porary or permanent infertility or subfertility [15] but fertil-
ity potential on an individual level often remains uncertain
following cancer in young adulthood [16, 17]. Results indi-
cate that a majority of young women diagnosed with cancer
experience fertility-related distress [7, 18], which has been
shown to be related to long-term depressive symptoms
[19]. In men fertility-related distress following cancer has
been studied to a very limited extent. One recent study
found that 28% of young men with testicular cancer re-
ported high levels of reproductive concerns approximately
2 years post-diagnosis [11]. In addition, impaired fertility
after testicular cancer appears to be related to decreased
quality of life and to lower emotional well-being [20, 21]. In
recent research, fear of infertility, or knowing that one’s
fertility has been compromised, has been associated with
negative effects on psychological wellbeing in men diag-
nosed with various types of cancer [22]. It has also been
reported that the threat of infertility is associated with
compromised self-esteem, sexuality and body-image in
both men and women diagnosed with cancer in
young adulthood [11, 16].
Several cancer diagnoses and/or their treatments have
potentially negative consequences on fertile ability or sex
life, including diagnoses that are common in young
adults: brain tumors, breast cancer, cervical cancer,
leukemia, lymphoma, ovarian cancer and testicular
cancer [1]. Still, research on reproductive and sexual
health issues in this group is limited and there is a lack
of longitudinal, large-scale studies using validated instru-
ments and reliable comparison data. As a result, knowledge
about the prevalence, predictors and trajectory of sexual
problems and fertility distress following a cancer diagnosis
in young adults is sparse. High quality longitudinal research
is needed to advance knowledge necessary to develop
cancer care adapted to the needs of this group.
The Fex-Can project
The project Fertility and Sexuality following Cancer
(Fex-Can) includes a cohort study with an embedded
randomized controlled trial (RCT) evaluating the effect
of a web-based intervention addressing sexual problems
and fertility-related distress, see study protocol for the
RCT [23]. This intervention was developed and evaluated
regarding its feasibility in collaboration with a group of
former cancer patients and significant others [24, 25]. The
present protocol describes the procedures for the Fex-Can
Cohort.
Objectives
The primary objective of the present study is to deter-
mine the prevalence and predictors of sexual dysfunction
and fertility-related distress following a cancer diagnosis
in young adulthood compared to prevalence rates for
the general population. Further aims are to investigate
the trajectories of these issues over time, the co-existence
between sexual dysfunction and fertility-related distress,
and the relation between these issues and body image,
anxiety and depression, health-related quality of life, self-
efficacy related to sexuality and fertility, and fertility-related
knowledge.
Methods/design
Study design
The study will have a population-based prospective cohort
design, investigating sexual dysfunction and fertility-related
distress in young adults diagnosed with cancer over 5 years
following diagnosis. The study will also include a cross-
sectional assessment of a comparison group, consisting of
young adults from the general population.
Setting
The diagnoses included in the Fex-Can Cohort are
selected based on the diseases and/or treatments having
potentially negative consequences on fertile ability or
sexual life. The incidence of the selected diagnoses in
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Sweden in 2016 was: brain tumors (n = 153), breast
cancer (n = 350), cervical cancer (n = 195), lymphoma
(n = 132), ovarian cancer (n = 39), and testicular cancer
(n = 220). Individuals diagnosed with leukemia were not
included in the Fex-Can Cohort due to an ongoing study
concerning fertility issues in this group. Participants will
be identified via the Swedish National Quality Registers
for Brain Tumors, Breast Cancer, Gynecological Oncol-
ogy, Lymphoma, and Testicular Cancer. All individuals
diagnosed with the selected diagnoses at ages 18–39
during a time period of 18 months will be approached
regarding study participation. Data collection will be
performed approximately 1.5 years after diagnosis (base-
line assessment) and 3 and 5 years after diagnosis. At
baseline most participants are expected to have completed
first-line treatment and be in the phase of returning to
work and studies. In order to time these data assessments
to participants’ time of diagnosis, data collections will be
performed in three waves (A-C), see Fig. 1. Data for the
comparison group will be collected on one occasion.
Recruitment
Cancer group
All individuals matching the inclusion criteria (see
below) will be approached regarding study participation
with a letter outlining the aims and procedures of the
study, the voluntary nature of participation, and a postal
survey. The survey will be possible to complete on paper
or via the web by using a unique participant code. On
request, participants may also have the possibility to
report their responses by phone. Two reminders will be
sent to non-responders. Participants will be offered two
cinema tickets (total value of approximately 20 Euro) as
incentives for completion of each assessment (baseline
and follow-ups).
Comparison group
A random sample of 2000 young adults (1000 women
and 1000 men) will be drawn from the Swedish popula-
tion register (SPAR) and approached regarding study
participation. The survey will be sent to potential partici-
pants, together with a letter with information about the
study including the voluntary nature of participation. As
for the cancer group, it will be possible to complete the
survey on paper, via the web or telephone, and two re-
minders will be sent to non-responders. The comparison
group will be offered the same incentive for participation
as the cancer group i.e., two cinema tickets. The
comparison group will only be assessed once.
Eligibility criteria
Cancer group
The following inclusion criteria will be used: All individ-
uals in Sweden in ages 18–39 who were diagnosed with
brain tumor, breast cancer, cervical cancer, lymphoma,
ovarian cancer, or testicular cancer between January
2016 and August 2017. Potential participants without
valid address information will be excluded. Furthermore,
approached individuals who on their own initiative in-
form us that they cannot complete the survey due to
cognitive impairment, poor health or non-ability to read
and/or understand Swedish will also be excluded.
Comparison group
For the comparison group the inclusion criteria will be:
Age 19–40 (matching the age of the cancer group at
baseline assessment) and registered as residents in
Sweden. Furthermore, similar to the cancer group,
approached individuals who on their own initiative
inform us that they cannot complete the survey due to
cognitive impairment, poor health or non-ability to read
and/or understand Swedish, will be excluded.
Variables
The primary outcomes will be sexual function and
fertility-related distress. Secondary outcomes will be
body image, anxiety and depression, health-related qual-
ity of life, self-efficacy related to sexuality and fertility,
and fertility-related knowledge. Primary and secondary
variables will be collected in the survey. Before conduct-
ing the Fex-Can Cohort, the primary outcomes were
tested in two pilot studies: one including young women
diagnosed with breast cancer (n = 181) [7], and one
including young men diagnosed with testicular cancer
Fig. 1 Fex-Can Cohort timeline for data collection of the cancer group
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(n = 111) [11]. The results showed the instruments to be
well accepted. All primary and secondary outcomes will
be included in the survey at each assessment. Addition-
ally, background variables (see below) will be collected
via the survey at baseline and at follow-ups. Clinical
variables (diagnosis, stage, treatment, relapse) will be
extracted from registry data and updated in connection
with each data collection. See Table 1 for overview of
assessments.
Cancer group – survey
Background variables Background variables collected
in the survey will include sociodemographic information
on country of birth, educational level, occupation,
partner relationship, children, and sexual orientation.
Information on current cancer treatment and the use of
fertility preservation procedures will also be included.
Sexual function The Patient-Reported Outcomes
Measurement Information System© Sexual Function and
Satisfaction Measure version 2 (SexFS v2) is a measure
assessing sexual function and satisfaction in men and
women regardless of sexual orientation [26]. Items in
the SexFS v2 are scored on a five-point scale (ranging
from 1 =None/Not at all to 5 = Very/A lot). In this study
four specific domains for women will be included: Vaginal
lubrication, Vaginal discomfort, Vulvar discomfort – clit-
oral, and Vulvar discomfort – labial. For males, the specific
domain Erectile function till be used. Additionally, four
gender-neutral domains will be included for all participants:
Interest in sexual activity, Orgasm – ability, Orgasm –
pleasure, and Satisfaction with sex life. Item response the-
ory is used to calculate domain scores, which are trans-
formed to a T-score metric where 50 represents the mean
for sexually active American adults (standard deviation =
10) [26]. The SexFS v2 has shown adequate content,
construct and known-groups validity as well as test-retest
reliability [26, 27]. The selected items and domains of the
SexFS v2 were translated into Swedish and linguistically
validated in accordance with the procedure developed by
FACITrans and PROMIS [28].
Fertility-related distress Fertility-related distress will
be assessed using the Reproductive Concerns After
Cancer (RCAC) scale. The RCAC is a multidimensional
measure, assessing a range of concerns related to fertility
and parenthood, developed and evaluated for young
adult female cancer survivors [29] and recently adapted
for male cancer survivors [30]. The scale includes 18
items in six dimensions (3 items each) scored on a five-
point scale (ranging from 1 = Strongly disagree to 5 =
Strongly agree). The following dimensions are included
in the RCAC: Fertility potential, Partner disclosure,
Child’s health, Personal health, Acceptance, and Becoming
pregnant/Achieving pregnancy. In each dimension, a high
level of reproductive concerns reflects fertility-related
distress and is defined as a mean score > 4. The RCAC has
demonstrated satisfactory internal consistency and con-
struct validity [19, 30, 31]. The original scale for females
was translated into Swedish by two bilingual researchers.
In parallel to this, a Swedish version for males was devel-
oped in collaboration with Dr. Gorman, creator of the ori-
ginal RCAC. Subsequently, these versions were evaluated
by one bilingual panel (n = 4), one lay panel (n = 7) and
one patient panel (n = 8), as well as by cognitive interviews
with 3 young persons with a cancer experience. The
Swedish versions have been used in women with breast
cancer [7] and men with testicular cancer [11] and shown
to be well accepted. Internal consistency in the female
Table 1 Overview and timing of assessments in the Fex-Can Cohort
Type of data Time of diagnosis / treatment start Baseline
1.5 years
Follow-up
3 years
Follow-up
5 years
Mode of administration
Survey data
Background variables X X X
Sexual function (SexFS v2) X X X
Fertility-related distress (RCAC) X X X
Anxiety and depression (HADS) X X X
Health-related quality of life
(EORTC QLQ-C30)
X X X
Body Image (BIS) X X X
Self-efficacy X X X
Fertility-related knowledge X X X
Clinical data Xa Xb Xb Xb
aExtraction of data from respective quality registry at time of baseline-assessment
bUpdated information extracted from the quality registries in connection to analyses
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version was shown to be good with exception for
‘Becoming Pregnant’ with a Cronbach’s α coefficient
of 0.54 [7]. In the male version, internal consistency
was acceptable (Cronbach’s α coefficients: 0.64–0.90)
in all dimensions [10].
Body image Body image will be assessed with the Body
Image Scale (BIS) that measures perception of one’s
body image associated with cancer and cancer treatment
[32]. The BIS comprises 10 items and responses are
given on a four-point scale (ranging from 0 =Not at all
to 3 = Very much) with higher scores indicating a more
negative body image. Total summary scores can range
between 0 and 30, and a total score exceeding 10 is
suggested to reflect a negative body image reaching a
clinical level [32, 33]. The BIS has shown high test-retest
reliability and satisfactory internal consistency in cancer
patients [32].
Anxiety and depression The Hospital Anxiety and
Depression scale (HADS) measures anxiety and depres-
sion in two subscales [34]. Each subscale consists of 7
items and responses are given on a four-point scale
(ranging between 0 and 3) with higher scores indicating
more distress. Subscale scores can range between 0 and
21, with scores above 7 indicating borderline or clinically
significant cases of anxiety or depression, respectively.
The subscales have been reported to have satisfactory
internal consistency and the concurrent validity has been
reported to be good to very good [35].
Health-related quality of life The EORTC QLQ-C30
(version 3.0) will be used to measure health-related quality
of life [36, 37]. The instrument includes five functional
scales, three symptom scales, a global health status scale,
and six single items. All scores will be linearly transformed
to a score between 0 and 100. For the functional and the
global QoL scales, higher scores indicate better health. For
the symptom scales, higher scores indicate more symptom
burden. The scale has demonstrated good psychometric
properties in cancer populations [36, 38].
Self-efficacy Self-efficacy related to sexuality and fertil-
ity will be assessed by study-specific questions measur-
ing confidence in one’s own ability to handle situations,
thoughts and emotions related to sexuality (6 items) and
to the threat of infertility (6 items). Examples of state-
ments assessing self-efficacy are “I feel confident that I
can handle negative thoughts and emotions in relation
to my sex life” and “I feel confident that I can cope with
meeting friends or relatives who are pregnant”. The
items are scored on a four-point scale (ranging from 1 =
Strongly disagree to 4 = Strongly agree) and an additional
response alternative “Not relevant”. Total mean scores will
be calculated, with higher scores indicating higher levels of
self-efficacy related to sexuality and fertility, respectively.
Fertility-related knowledge Perceived level of know-
ledge about general and cancer-related fertility issues
will be examined by a study-specific questionnaire with
10 items rated on a four-point scale (ranging from 1 =
Disagree completely to 4 = Agree completely). Examples
of items are: “I have good knowledge regarding the
chance of becoming pregnant at one attempt” and “I
have good knowledge regarding the effect of cancer and
cancer treatments on reproductive ability”. Total mean
scores will be calculated, with higher scores indicating
higher levels of perceived fertility-related knowledge.
Cancer group - registry data
After receiving formal consent from each registry, the
following clinical data will be collected from the Swedish
National Quality Registries for Brain Tumors, Breast
Cancer, Gynecological Oncology, Lymphoma, and Tes-
ticular Cancer: date of diagnosis, clinical stage, type of
treatment, relapse, adverse events, secondary cancers
and performed fertility preservation. The clinical vari-
ables were selected in close collaboration with represen-
tatives from each National Quality Registry.
Comparison group - survey
The survey administered to the comparison group will
include the same instruments as for the cancer group
with the exception of the study-specific measures of
fertility-related knowledge and self-efficacy related to
fertility. Furthermore, specific items related to having
had cancer will be deleted from the BIS (5 items) and
the RCAC (9 items constituting 3 dimensions: Partner
disclosure, Child’s Health, Personal Health). The short-
ened versions of the BIS and RCAC have not been
validated. However, the shortened BIS has been used in
a previous study on sexual functioning in the general
Dutch population showing a Cronbach’s α coefficient of
0.86 [39].
Administration of instruments
Study-specific items and instruments to the cancer
group will be administered in the same order at all
assessments: BIS; RCAC; Self-efficacy Fertility; Fertility-
related knowledge; Self-efficacy Sexuality; SexFS v2;
HADS; and EORTC QLQ-30. The comparison group
will only be assessed once with study-specific items and
instruments, given in the same order as for the cancer
group.
Sample size
Based on official statistics on cancer incidence in
Sweden [2, 40] the eligible population is estimated to
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approximately 1500 for the inclusion period. Based on
our experience of moderate response rates (50–60%) in
surveys on sensitive issues in this age group when no
incentives were offered [7, 11], we expect the addition of
incentives (2 cinema tickets) to result in a larger propor-
tion of responders. An estimated response rate of 70%
would result in 1050 participants at baseline. At baseline,
a majority of participants (≈80%, n = 840) are expected
to rate sexual dysfunction or fertility-distress meeting
the inclusion criteria for the embedded RCT [23]. Of
those invited to the RCT, about half are expected to
consent participation (N = 420) and these will be ex-
cluded for further follow-up in the Fex-Can Cohort,
leaving 630 participants for the longitudinal analyses. At-
trition in the Fex-Can Cohort due to deaths and other
reasons for non-response is estimated to 15% at follow-
ing assessments, giving an estimated response rate at T2
(n = 535) and T3 (n = 454). Sample size determination
was based on the recommendation to include at least 5
events of the dependent variable of interest (in this case:
the primary outcome measures SexFS and RCAC) for
each independent variable included in the multivariable
logistic regression models [41]. Thus, we estimated that
at least 50 events of the dependent variable in the
sample are required in order to include up to ten inde-
pendent variables. Based on the incidence rates of the
selected diagnoses, we expected a distribution of ap-
proximately 65% women and 35% men in the eligible
sample. Previous data of sexual dysfunction and fertility
distress in the Swedish setting [7, 11] indicate that the
number of events of the dependent variables at baseline
is ≈30% for males and ≈60% for females. Based on these
numbers, we estimate the sample size to be sufficient for
determination of potential predictors for both sexes at
all assessment occasions, including the 5-year follow-up.
As the Fex-Can Cohort is an observational study, no
formal power calculation was conducted.
Statistical methods
The study will be reported following the STROBE state-
ment [42] and the SPIRIT-PRO Extension [43]. Descrip-
tive statistics will be used to determine the prevalence of
sexual dysfunction and fertility-related distress by diag-
nosis and sex. These will be presented as means and
standard deviations and as percentages of participants
above the described cut-offs for these outcomes. Preva-
lence rates in the cancer group will be compared to
prevalence rates in the general population by sex and
age group, using Students’ t-test and χ2 tests. To deter-
mine predictors for sexual dysfunction and fertility-
related distress at each assessment we will perform logis-
tic regression models for each primary outcome (SexFS
v2-domains and RCAC-dimensions) for the whole group
and by sex. Independent variables will include sex
(whole group), partner status, parenthood status, child
wish (only for RCAC), satisfaction with sex life pre-
diagnosis (only for SexFS v2), diagnosis, treatment inten-
sity, body image, anxiety, and depression. Trajectories of
these issues over time (T1, T2 and T3) will be analyzed
with linear mixed models. Relations between sexual dys-
function and fertility-related distress, and between these
issues and our secondary outcomes, will be analyzed
with Pearson’s correlation coefficients. Statistical ana-
lyses will be performed in collaboration with external
statisticians.
Ethics and dissemination
Research ethics approval
Ethical approval has been obtained for the study proce-
dures by the Regional Ethical Review Board in
Stockholm, Sweden (Dnr: 2013/1746–31/4; 2014/2244–
32; 2017/916–32; 2017/1416–32).
Confidentiality
All participants will receive a unique code number indi-
cated on the survey. The code key will be stored separate
from the research data and will only be accessible by
members of the research team. All data will be handled
and stored according to the EU General Data Protection
Regulation (GDPR). This includes storage of paper re-
cords in locked spaces on institution premises and stor-
age of electronic records on secure, password-protected
servers, with access restricted to the research team. Data
will be shared with external statisticians through secure
servers. The research team members have formal train-
ing in research ethics, which is a mandatory part of doc-
toral education at the institution. Adherence to research
ethics and the study protocol will be monitored by the
principal investigators (first and last authors) at regular
project meetings and in their supervision of doctoral stu-
dents and post-doctoral researchers involved in the Fex-
Can project.
Dissemination policy
The results from the study will be communicated to the
scientific, clinical and patient communities through
open-access publications in scientific peer-reviewed
journals. Additionally, presentations of the results will be
made at international and national clinical and scientific
conferences and in other contexts.
Discussion
This population-based cohort study aims to determine
the prevalence and predictors of sexual dysfunction and
fertility-related distress in young adults diagnosed with
cancer. The results of the study will increase under-
standing of the trajectories of sexual dysfunction and
fertility-related distress over 5 years following diagnosis.
Wettergren et al. BMC Cancer          (2020) 20:722 Page 6 of 9
Our study design includes a large nationwide sample
of young adults diagnosed with different cancers and will
therefore establish prevalence rates of sexual dysfunction
and fertility-related distress over the first 5 years after
diagnosis. One of the selected diagnoses, brain tumors,
is a cancer often excluded in this kind of research and
the group’s sexual dysfunction and fertility-related
distress is still largely unknown. Potential participants
will be identified through National Quality Registers
with excellent coverage, ensuring that all individuals in
the age group diagnosed with the selected cancers will
be approached [44]. The design also allows for analyses
of non-responders and attrition including highly reliable
clinical variables. At the baseline assessment some
patients may still be on treatment (e.g. lymphoma and
breast cancers) and others will have finished their treat-
ment (e.g. testicular cancer). Therefore, treatment status
will be described in detail for each diagnosis when
reporting prevalence at baseline, and all models will
control for current treatment status. While most of the
selected patient-reported outcome measures are stan-
dardized instruments, it should be noted that the study-
specific measures, as well as the shortened versions of
the BIS and RCAC for the comparison group, have not
been validated. With a young adult comparison group
assessed with the same standardized measures it will be
possible to determine to what extent the self-rated prob-
lems are related to being treated for cancer. As the
prevalence of sexual dysfunction in women and men has
been reported to vary between countries [45, 46], the
use of a comparison group randomized from the total
general population in the country is a strength. How-
ever, the fact that the comparison group is only assessed
at one time point is a limitation as it does not allow
comparison of trajectories of these issues over time.
There are also a few challenges to be considered.
Achieving high response rates to surveys targeting cancer
populations and the general population have become chal-
lenging particularly among young people. In addition, at-
trition may introduce bias and limit the possibility to
perform subgroup analyses. We have tried to minimize
this risk by offering the choice of answering the survey on
paper, the web or via a telephone interview and offer in-
centives for each answered survey to reach the highest
possible response rate. Furthermore, great care has been
taken to phrase written information in order to optimize
inclusion of both men and women in the study, as well as
individuals with different levels of education. The survey
is only available in Swedish, and those who do not under-
stand Swedish (cancer group and comparison group) will
be not be able to participate in the study. However, we do
offer the possibility to answer the questions by phone to
facilitate participation for those who understand Swedish
but do not read the language.
To conclude, the Fex-Can Cohort study will elucidate
concerns and problems related to sexual life and fertility,
as experienced by young adults with cancer. The results
will inform different groups of stakeholders including
healthcare providers, patients and their partners. The
findings will form a basis for developing interventions to
alleviate sexual problems and fertility-related distress in
young adults with cancer in the short and long term.
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